Pharmaceutical Technology on MSN2d
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
Opko Health, Entera Bio enter collaboration agreement for GLP-1/glucagon peptide
OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...
Opko Health, Entera Bio enter into collaboration agreement
OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...
Morningstar24d
Entera Bio to Participate in Upcoming Events
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in ...
Frontiers3y
Editorial: Proglucagon-Derived Peptides
However, recent research challenges this tissue selectivity, demonstrating that under certain circumstances, alpha-cells appear to produce GLP-1, oxyntomodulin and glicentin whereas the intestinal ...